| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(97)03022-5 |
| P698 | PubMed publication ID | 9288042 |
| P50 | author | Joanna Wardlaw | Q25272201 |
| P2093 | author name string | C P Warlow | |
| C Counsell | |||
| P2860 | cites work | Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients | Q54066813 |
| Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) | Q55063586 | ||
| Why do we need systematic overviews of randomized trials? | Q69169993 | ||
| Multicentre Acute Stroke Trial--Italy | Q70994807 | ||
| Patient preferences for stroke outcomes | Q72157125 | ||
| THERAPEUTIC THROMBOLYSIS IN CEREBRAL THROMBOEMBOLISM. DOUBLE-BLIND EVALUATION OF INTRAVENOUS PLASMIN THERAPY IN CAROTID AND MIDDLE CEREBRAL ARTERIAL OCCLUSION | Q76607065 | ||
| ANTICOAGULANTS PLUS STREPTOKINASE THERAPY IN PROGRESSIVE STROKE | Q76848136 | ||
| Mortality by cause for eight regions of the world: Global Burden of Disease Study | Q29615121 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group | Q30467048 | ||
| Thrombolysis in acute ischemic stroke: does it work? | Q35537085 | ||
| A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction | Q35879688 | ||
| The relation between treatment benefit and underlying risk in meta-analysis | Q39453386 | ||
| Controversies in meta-analysis: the case of the trials of serum cholesterol reduction | Q39522433 | ||
| Trials of streptokinase in severe acute ischaemic stroke | Q43985178 | ||
| Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke | Q48485705 | ||
| Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. | Q48913792 | ||
| Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea | Q48936157 | ||
| Thrombolytic therapy with streptokinase in acute ischemic stroke. | Q48962264 | ||
| Thrombolysis with fibrinolysin in cerebral arterial occlusion. | Q51319854 | ||
| P433 | issue | 9078 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| thrombolysis | Q1931577 | ||
| P304 | page(s) | 607-614 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke | |
| P478 | volume | 350 |
| Q73238461 | Acute Ischemic Stroke |
| Q89975772 | Advances in Sonothrombolysis Techniques Using Piezoelectric Transducers |
| Q33278117 | Advances in ischemic stroke treatment: neuroprotective and combination therapies |
| Q33809694 | Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign |
| Q38955110 | Amygdalin isolated from Semen Persicae (Tao Ren) extracts induces the expression of follistatin in HepG2 and C2C12 cell lines |
| Q35198028 | Animal models of stroke: do they have value for discovering neuroprotective agents? |
| Q53461993 | Anterior cerebral artery emboli in combined intravenous and intra-arterial rtPA treatment of acute ischemic stroke in the IMS I and II trials. |
| Q73496019 | Antithrombotic and thrombolytic therapy for ischemic stroke |
| Q28195140 | Antithrombotic drug treatment of pediatric patients with ischemic stroke |
| Q28162603 | Aspirin and heparin in acute ischaemic stroke in older patients |
| Q35074272 | Astrocytes and stroke: networking for survival? |
| Q33244267 | Avoidable mortality across Canada from 1975 to 1999 |
| Q53085491 | Basics of systematic reviews and meta-analyses for the nephrologist. |
| Q34293439 | Candidates for thrombolytic treatment in acute ischaemic stroke--where are our patients in Hong Kong? |
| Q40813700 | Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding |
| Q28546284 | Comparative Metabolomic Analysis of the Neuroprotective Effects of Scutellarin and Scutellarein against Ischemic Insult |
| Q48950181 | Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. |
| Q42719045 | Concomitant induction of heme oxygenase-1 attenuates the cytotoxicity of arsenic species from lumbricus extract in human liver HepG2 cells. |
| Q77731201 | Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase |
| Q34271967 | Controversies about tissue plasminogen activator: extending the window of therapy |
| Q36059382 | Current management of acute ischemic stroke. Part 1: Thrombolytics and the 3-hour window |
| Q48430328 | Design of a multicentre study on neurosonology in acute ischaemic stroke. A project of the neurosonology research group of the World Federation of Neurology. |
| Q35552845 | Development of the Nitrone‐Based Spin Trap Agent NXY‐059 to Treat Acute Ischemic Stroke |
| Q35001038 | Development of thrombolytic therapy for stroke: a perspective |
| Q33609391 | Diagnosis and treatment of ischemic stroke |
| Q74598571 | Does neuroprotection improve stroke outcome? |
| Q40834591 | Drug therapy for acute ischaemic stroke: risks versus benefits |
| Q95283203 | ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
| Q33634715 | Early postischemic hyperperfusion: pathophysiologic insights from positron emission tomography |
| Q28192804 | Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain |
| Q73503184 | Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate |
| Q73111221 | Evidence-based emergency medicine: updates, feedback, and links |
| Q37963892 | Gene-drug interaction in stroke |
| Q37206266 | Genetics of stroke: a review of recent advances. |
| Q34566668 | Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment |
| Q35842257 | Hibernation, a model of neuroprotection |
| Q45943825 | High-dimensional therapeutic inference in the focally damaged human brain. |
| Q37903963 | Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin |
| Q77518317 | If I had a stroke . . . |
| Q24317703 | Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke |
| Q33698627 | Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies |
| Q36215235 | Investigating potentially salvageable penumbra tissue in an in vivo model of transient ischemic stroke using sodium, diffusion, and perfusion magnetic resonance imaging |
| Q31019890 | Ischaemic stroke in dogs and humans: a comparative review |
| Q33539477 | Limiting neurological damage after stroke: a review of pharmacological treatment options |
| Q48063341 | Loss and recovery of functional connectivity in cultured cortical networks exposed to hypoxia |
| Q57130870 | Lost in translation |
| Q36053335 | Low use of long-term hormone replacement therapy in Denmark |
| Q30652153 | Magnetic resonance prediction of outcome after thrombolytic treatment |
| Q28196668 | Management of acute stroke |
| Q34271952 | Medical therapy for acute ischemic stroke |
| Q35648315 | MiR-335 Regulates Hif-1α to Reduce Cell Death in Both Mouse Cell Line and Rat Ischemic Models |
| Q33838053 | Neurological emergencies: acute stroke |
| Q34346609 | Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neurodegenerative diseases |
| Q46921241 | Neuroprotective effect of diphenyl diselenide in a experimental stroke model: maintenance of redox system in mitochondria of brain regions |
| Q36104050 | Neuroprotective herbs for stroke therapy in traditional eastern medicine |
| Q35974043 | Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke |
| Q46865977 | PAK: an essential motif for forming beta-turn structures and exhibiting the thrombolytic effect of P6A and its analogs |
| Q37024492 | Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly |
| Q73870752 | Potentiation of NMDA receptor function by the serine protease thrombin |
| Q33931454 | Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features |
| Q41877528 | REACH MUSC: A Telemedicine Facilitated Network for Stroke: Initial Operational Experience |
| Q33704535 | Recent Advances. Neurology. |
| Q30626736 | Recent advances in the diagnosis and treatment of stroke |
| Q34432109 | Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents |
| Q33951299 | Reperfusion therapy for stroke |
| Q48393238 | Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy |
| Q58805396 | Scutellarin protects oxygen/glucose-deprived astrocytes and reduces focal cerebral ischemic injury |
| Q30305943 | Serine proteases and brain damage - is there a link? |
| Q33662944 | Stroke in childhood. |
| Q37635110 | Stroke pharmacogenomics |
| Q48358262 | Stroke treatment: time is brain. |
| Q36141885 | Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury |
| Q30747694 | Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage |
| Q34551522 | The -7351C/T polymorphism in the TPA gene and ischemic stroke risk: a meta-analysis |
| Q33900888 | The classics: a tribute to the fiftieth anniversary of the randomized clinical trial |
| Q33917662 | The evolution of stroke units-towards a more intensive approach? |
| Q36381508 | The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro |
| Q30749058 | The very acute stroke treatment: fibrinolysis and after |
| Q33593063 | Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care |
| Q24194788 | Thrombolysis for acute ischaemic stroke |
| Q24240067 | Thrombolysis for acute ischaemic stroke |
| Q24247962 | Thrombolysis for acute ischaemic stroke |
| Q33932122 | Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial. |
| Q30596908 | Thrombolysis in Acute Stroke Pooling Project: a meta-analysis on individual patient data |
| Q34164541 | Thrombolysis in acute ischaemic stroke |
| Q48294695 | Thrombolytic Therapy in Acute Ischemic Stroke |
| Q73883013 | Thrombolytic therapy for acute ischaemic stroke |
| Q93905041 | Thrombolytic therapy for acute ischaemic stroke |
| Q73883015 | Thrombolytic therapy for acute ischaemic stroke. ECASS Study Group |
| Q33873285 | Thrombolytic therapy for stroke: a review with particular reference to elderly patients. |
| Q35081866 | Thrombolytic therapy: clinical applications |
| Q33789540 | Thrombolytic treatment for acute ischaemic stroke: consent can be ethical |
| Q81244699 | Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation |
| Q34653391 | Why do clinicians sometimes find it difficult to use the results of systematic reviews in routine clinical practice? |
| Q79928804 | [Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke--update 2003. I. organization and acute therapy] |
| Q34792605 | microRNAs Involved in Regulating Spontaneous Recovery in Embolic Stroke Model |
| Q47981603 | t-PA in acute ischemic stroke. |
Search more.